Cover Image
市場調查報告書

中國的血液製劑產業分析

Research Report on China Blood Product Industry, 2011-2016

出版商 China Research and Intelligence 商品編碼 355895
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的血液製劑產業分析 Research Report on China Blood Product Industry, 2011-2016
出版日期: 2016年04月07日 內容資訊: 英文 50 Pages
簡介

中國國內現在血液製劑廠商有33家公司,不過,實際進行生產的只有20家公司。另一方面,如果依據中國的14億總人口,血液製劑的潛在需求規模達到12,000噸,不過,實際的需求量是8,000噸,並且中國國內的實際的供給量停留在5,000噸。中國的情況是,血漿的供給量有限是最大的課題,血液製劑廠商透過捐血據點的增設以確保供給量為目標。今後,隨著血漿供給量的規定放緩,廠商間競爭也將以研究開發 (R&D) 能力和銷售能力為中心變化。

本報告提供中國國內的血液製劑產業相關分析,目前產業結構、趨勢和到目前為止的發展途徑,政府的政策,市場規模的變化及預測 (過去、今後5年份),主要企業簡介,市場競爭的狀態等調查評估。

第1章 血液製劑概要

  • 定義
  • 特徵
  • 分類
  • 血液製劑相關的產業政策
    • 管轄政府機關
    • 企業成立相關政策
    • 原料採購相關政策
    • 血液製劑的生產相關政策
    • 血液製劑的流通相關政策
  • 中國的血液製劑產業概況
    • 法規政策
    • 血液的使用率
    • 產業的特徵

第2章 全球血液製劑產業概況 (過去5年份)

  • 產業概要
    • 發展過程
    • 競爭模式
    • 供應結構
    • 需求結構
  • 全球 (中國之外) 的主要的血液製劑廠商
    • Baxter International
    • CSL Behring
    • Grifols SA

第3章 中國的血液製劑產業的供需情形 (過去5年份)

  • 發展過程
  • 進入障礙
    • 政策障礙
    • 血液供給來源的障礙
    • 技術、品管能力
  • 供給情形
    • 目前生產情形:概要
    • 中國國內的主要的血液製劑廠商
    • 白蛋白的生產能力、生產量
    • 免疫球蛋白的生產能力、生產量
    • 凝血因子的生產能力、生產量
  • 需求情形
    • 白蛋白
    • 免疫球蛋白
    • 凝血因子

第4章 中國的血液製劑產業的主要企業 (過去5年份)

第5章 中國的血液製劑產業趨勢預測 (今後5年份)

  • 供給量的預測
    • 血漿供給量的預測
    • 大量交付量的預測
    • 生產能力的擴張預測
  • 需求量的預測
    • 需求趨勢的預測
    • 市場規模的預測
  • 市場競爭的預測
    • 受歡迎的產品的預測
    • 競爭模式的預測

圖表一覽

目錄
Product Code: 1604337

Blood products made by segregating and purifying all kinds of proteins in the blood plasma consists of albumin, immunoglobulin, thrombinogen and other products. China's enterprises mainly produce 9 kinds of products in the first three categories.

The high concentration rate of the global blood product market is embodied in the three companies of developed countries accounting for more than 80% of the global market. The current global blood market remains relatively stable, of which the emerging economy is the main motivation of growth.

By the end of 2015, there were 33 blood product manufacturing enterprises certified by the government in China, but in fact, only 20 of them were in production. Since 2012, mergers and acquisitions are common in China's blood product industry. For example, Jiangxi Boya Bio-Pharmaceutical Co., Ltd. acquired partial stock rights of Zhejiang Haikang Biologicals Co., Ltd. Beijing Tiantan Biological Products Co., Ltd. purchased Chengdu Rosen Pharmaceutical Co., Ltd. Watson Biological Company acquired Hebei Docan Pharmaceutical Co., Ltd. Shanghai RAAS Blood Products Co., Ltd. purchased Zhengzhou Banghe Pharmaceutical Co., Ltd. China National Biotec Group acquired Guiyang Qianfeng Biological Products Co., Ltd. and Xi'an Huitian Blood Products Co., Ltd. Humanwell Healthcare Group Co., Ltd. purchased Wuhan Rui De Biological Products Co., Ltd.

In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons. For example, the demand for blood products of about 1.4 billion population of China should be 12,000 tons calculated according to per capita demand of the normal blood products of the World Health Organization, which is far more than the actual supply of China.

In China's blood product industry, the scale of the blood plasma has been the main bottleneck restricting the development of blood product industry. The quality and quantity of plasma stations are of vital importance.

In 2001, Chinese government announced that no new blood product manufacturing enterprises would be approved to ensure the safety of blood and its products, and block the spread of HIV through collection and supply of blood .

In 2008, Chinese government formulated the regulations that the plasma collection regions should guarantee the quantity of the plasma donors, which can satisfy no less than 30 tons' collection of source plasma.

In 2011, Guizhou government announced the program of adjusting the settings of blood services. The plasma collection stations decreased from 20 to 4, of which Hualan Biological Engineering Co., Ltd., the blood product giant, suffered the most. The plasma stations of Guizhou Province decreased from 6 to 1, having reduced half of the corporate source plasma supply.

Lack of the local blood products, but Chinese government has issued strict regulations on the import of blood products. Only human serum albumin and three kinds of thrombinogen are allowed to be imported.

In recent years, the competitiveness of China's blood product market has been mainly determined by the amount of blood plasma resources. Under the tense condition of source plasma supply, blood product manufacturing enterprises will obtain more space for survival and development with more blood plasma stations and source plasma.

On June 1, 2015, China National Development and Reform Commission released the highest price limit on blood products, and companies can name their own prices. In the first quarter of 2016, the price of fibrinogen and tetanus immunoglobulin in Chinese market increases by 80%-130%, and the price of intravenous gammaglobulin increases by 10%-20%. In addition to the relaxed price regulations, another support policy is to gradually release the auditing of plasma collection stations. At the beginning of 2013, Chinese government released the auditing standards for plasma collection stations. By the end of 2013, there had been no more than 160 plasma collection stations in China. There were more than 200 plasma collection stations at the end of 2015. In spite of the most plasma collection stations, Shanghai RAAS Blood Products Co. Ltd. had possessed only 30 plasma collection stations in operation by the end of 2015.

In the long run, the competitiveness of blood product manufacturing enterprises mainly depends on the ability of research & development and sales. In a few years, the tense situation of China's raw blood plasma's supply will be eased. Only enterprises with strong ability of research & development and sales and a sound product line can win the competition.

There are only two channels for overseas blood product enterprise to enter Chinese market. One is to export products to China directly. The other one is to enter Chinese market indirectly through such means as equity acquisition.

The report is accomplished on the basis of deep market research. Through this report, the readers shall acquire the following information:

  • Current Situation of the Global Blood Product Industry
  • Development History and Current Situation of China's Blood Products
  • Government Policies of China's Blood Product Industry
  • Niche Products' Current Situation of China's Blood Product
  • Market Competition of China's Blood Product Industry
  • China's Major Blood Product Enterprises and Their Operation Status
  • Development Trend of China's Blood Product Industry

The Following Enterprises and People Are Recommended to Purchase This Report:

  • Blood Product Manufacturing Enterprises
  • Blood Product Regulatory Agency
  • Investors /Research Agencies Focusing on Blood Product Industry

Table of Contents

1. Introduction of Blood Products

  • 1.1. Definition
  • 1.2. Characteristics
  • 1.3. Classification
    • 1.3.1. Albumin
    • 1.3.2. Immune Globulin
    • 1.3.3. Coagulation Factors
    • 1.3.4. Other Categories
  • 1.4. Industrial Policies on Blood Product
    • 1.4.1. Industrial Competent Departments
    • 1.4.2. Policies on Enterprise Establishment
    • 1.4.3. Policies on Raw Material Purchasing
    • 1.4.4. Policies on Blood Product Production
    • 1.4.5. Policies on Blood Product Circulation
  • 1.5. Overview on China Blood Product Industry
    • 1.5.1. Regulatory Policies
    • 1.5.2. Blood Utilization Ratio
    • 1.5.3. Industry Characteristics

2. Overview of Global Blood Product Industry, 2011-2015

  • 2.1. Industry Overview
    • 2.1.1. Development Process
    • 2.1.2. Competition Pattern
    • 2.1.3. Supply Status
    • 2.1.4. Demand Status
  • 2.2. Major Blood Product Manufacturers in the Globe (Except China)
    • 2.2.1. Baxter International
    • 2.2.2. CSL Behring
    • 2.2.3. Grifols SA

3. Supply and Demand Status of China Blood Product Industry, 2011-2015

  • 3.1. Development Process
  • 3.2. Barriers to Entry
    • 3.2.1. Policy Barriers
    • 3.2.2. Blood Source Barrier
    • 3.2.3. Technology and Quality Control Capability
  • 3.3. Supply
    • 3.3.1. Overview on Production Status
    • 3.3.2. Major Blood Product Manufacturers in China
    • 3.3.3. Production Capacity and Output Volume of Albumin
    • 3.3.4. Production Capacity and Output Volume of Immune Globulin
    • 3.3.5. Production Capacity and Output Volume of Coagulation Factor
  • 3.4. Demand Status
    • 3.4.1. Albumin
    • 3.4.2. Immune Globulin
    • 3.4.3. Coagulation Factors

4. Major Enterprises of China Blood Product Industry, 2011- 2015

  • 4.1. Shanghai RAAS Blood Products Co. Ltd.
    • 4.1.1. Enterprise Profile
    • 4.1.2. Production Capacity
  • 4.2. Hualan Biological Engineering Co., Ltd.
  • 4.3. Beijing Tiantan Biological Products Co., Ltd. (Subsidiary of China National Biotec Group Company Limited)
  • 4.4. Guangdong Shuanglin Bio-pharmaceutical Co., Ltd.
  • 4.5. Jiangxi Boya Bio-pharmaceutical Co., Ltd.
  • 4.6. Hunan Nanyue Pharmaceutical Co., Ltd.
  • 4.7. Wuhan Rui De Biological Products Co., Ltd.
  • 4.8. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 4.9. Green Cross Biological Products Co., Ltd.
  • 4.10. Guiyang Qianfeng Biological Products Co., Ltd.
  • 4.11. Anhui Da'an Biological Products Co., Ltd.
  • 4.12. Shenzhen Weiguang Biological Products Co., Ltd.
  • 4.13. Shandong Taibang Products Co., Ltd.
  • 4.14. Subordinate Institutions of Biological Products of China National Biotec Group

5. Forecast on Development of China Blood Product Industry, 2016-2020

  • 5.1. Supply Forecast
    • 5.1.1. Forecast on Plasma Volume
    • 5.1.2. Forecast on Lot Release
    • 5.1.3. Forecast on Production Capacity Expansion
  • 5.2. Demand Forecast
    • 5.2.1. Demand Trend Prediction
    • 5.2.2. Prediction of Market Size
  • 5.3. Forecast on Market Competition
    • 5.3.1. Forecast on Popular Products
    • 5.3.2. Forecast on Competition Pattern

Selected Charts

  • Chart Common Varieties and Functions of Albumin
  • Chart Common Varieties and Functions of Immune Globulin
  • Chart Common Varieties and Functions of Coagulation Factors
  • Chart Varieties and Functions of Other Blood Products
  • Chart Important Policies of China Blood Product Industry
  • Chart Top 5 Blood Product Enterprises in the World, 2015
  • Chart Global Blood Product Plasma Volume and Forecast, 2009- 2020
  • Chart Global Blood Product Market Scale and Forecast, 2009-2020
  • Chart Market Share by Region in the Globe
  • Chart Market Share by Category in the Globe
  • Chart Sales Scale of Baxter International Blood Products, 2011-2015
  • Chart Sales Scale of CSL Behring Blood Products, 2011-2015
  • Chart Sales Scale of Grifols Blood Products, 2011-2015
  • Chart Blood Product Plasma Volume in China, 2009-2015
  • Chart Lot Release Volume of Blood Products in China, 2009-2015
  • Chart Major Blood Product Manufacturers in China
  • Chart Lot Release Volume of Albumin Products in China, 2009- 2015
  • Chart Lot Release Volume of Immune Globulin Products in China, 2009-2015
  • Chart Lot Release Volume of Coagulation Factor Products in China, 2009-2015
  • Chart Market Scale of China Blood Products, 2011-201528
  • Chart Market Scale of Albumin Blood Products in China, 2011-2015
  • Chart Market Scale of Immune Globulin Blood Products in China, 2011-2015
  • Chart Market Scale of Coagulation Factor Blood Products in China, 2011-2015
  • Chart Products of Shanghai RAAS Blood Products Co. Ltd.
  • Chart Plasma Volume of Shanghai RAAS Blood Products Co. Ltd., 2011-2015
  • Chart Plasma Collecting Stations Newly Approved by the Chinese after 2009
  • Chart Forecast on Plasma Volume in China, 2016-2020
  • Chart Forecast on Lot Release of China Blood Products, 2016-2020
  • Chart Comparison of Annual Blood Product Consumption Per Capita Between Developed Countries and China, 2015
  • Chart Forecast on the Market Scale of Blood Products in China, 2016-2020
  • Chart Forecast on the Market Scale of Albumin Products in China, 2016-2020
  • Chart Forecast on the Market Scale of Immune Globulin Products in China, 2016- 2020
  • Chart Forecast on the Market Scale of Coagulation Factor Products in China, 2016-2020
Back to Top